Brainstorm Cell Therapeutics Inc.
BCLI- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001137883
No open-market purchases or sales by Brainstorm Cell Therapeutics Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Brainstorm Cell Therapeutics Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 32 | 34 | +2 |
| Shares | 1.02M | 392.8K | −630.2K (−61.6%) |
| Value | $1.09M | $264.0K | −$827.2K (−75.8%) |
New holders (7)
Institutions that held Brainstorm Cell Therapeutics Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Gunderson Capital Management Inc. | 25,950 | $29.1K | 0.01% |
| Traynor Capital Management, Inc. | 11,000 | $12.2K | 0.00% |
| LPL Financial LLC | 10,698 | $12.0K | 0.00% |
| Almanack Investment Partners, LLC. | 10,000 | $11.2K | 0.00% |
| Raymond James Financial Inc | 5,158 | $5.78K | 0.00% |
| Harbour Investments, Inc. | 3,559 | $3.99K | 0.00% |
| Citigroup Inc | 663 | $743 | 0.00% |
Sold out (5)
Institutions that held Brainstorm Cell Therapeutics Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Armistice Capital, LLC | 690,666 | $870.2K |
| Two Sigma Securities, LLC | 16,153 | $20.4K |
| JPMorgan Chase & Co | 171 | $215 |
| Tower Research Capital LLC (TRC) | 135 | $170 |
| Centricity Wealth Management, LLC | 20 | $25 |